In September 2022, the U.S. Food and Drug Administration (FDA) approved PEDMARK® (sodium thiosulfate) to reduce the risk of cisplatin-induced hearing loss in children receiving this cancer treatment. Cisplatin is a commonly-used chemotherapeutic agent for treatment of brain, bone, and liver cancers. During treatment, the accumulation of cisplatin in the inner ear may result in sensorineural hearing loss, particularly in children.
The road to this FDA approval began almost 30 years ago in an Oregon Health and Science University (OHSU) laboratory led by Edward Neuwelt, MD, professor and lead researcher in the Department of Neurology at OHSU. Their bench-to-bedside approach to examining the benefits of this drug required intense collaboration among researchers, scientists, clinicians, families, and cancer survivors. The FDA has approved the use of PEDMARK® for patients ranging in age from one month up to 18 years who have localized tumors.
Reference
Oregon Health and Science University News. (2023) Driven by OHSU research, FDA approves new drug to prevent hearing loss in children with cancer (accessed February 16, 2023).
Related Posts
Recent Posts
A Virtual Reality System for Delivery of Military-Specific Vestibular Rehabilitation After Mild Traumatic Brain Injury: The Praxis Study Protocol
In an article by Alroumi et al. (2025), treatment of mild traumatic brain injury (mTBI) through the use of virtual reality (VR) system was investigated….
From Capitol Hill to Your Clinic: SPAN July Meeting on Medicaid Cuts
The State Policy Advocacy Network (SPAN) will convene again on July 29 for a critical meeting about Medicaid funding. SPAN brings together nationwide audiologists and…
EHDI Program at Risk
On April 1, President Trump’s administration eliminated the entire branch of the Early Hearing Detection and Intervention (EHDI) program that works with states to analyze…